Articles from Shaanxi Micot Pharmaceutical Technology Co., Ltd.

Micot Pharma Showcases First-in-Class, Brain-Penetrant TrkB Agonist MT200605 at World Stroke Congress, Building the Case for Global Partnerships and Commercialization

By Shaanxi Micot Pharmaceutical Technology Co., Ltd. · Via ACN Newswire · October 26, 2026

Micot Pharma Debuts MT200605 Huntington's Disease Research in a Poster Presentation at MDS 2026 and Expands Development into Neurodegenerative Diseases

By Shaanxi Micot Pharmaceutical Technology Co., Ltd. · Via ACN Newswire · October 12, 2026

Micot's XTL6001 Featured in Two EASD Presentations: MasR/GCGR/GLP-1R Triple-Agonist Mechanism Opens a Differentiated Path Across Metabolic and Renal Disease

By Shaanxi Micot Pharmaceutical Technology Co., Ltd. · Via ACN Newswire · October 5, 2026

Micot Pharma Reports Positive Operating Cash Flow and Advances Late-Stage Pipeline in 1H 2026

By Shaanxi Micot Pharmaceutical Technology Co., Ltd. · Via ACN Newswire · August 31, 2026

Micot Pharma's MT200605 Achieves Primary Endpoint in Phase II Trial, Novel Integrated Multi-stage Neuroprotection Mechanism to Be Presented at WSC 2026

By Shaanxi Micot Pharmaceutical Technology Co., Ltd. · Via ACN Newswire · August 7, 2026